id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0597-0001,FDA,FDA-2011-D-0597,Draft Guidance for Industry; Availability: Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring,Notice,Notice of Availability,2011-08-29T04:00:00Z,2011,8,2011-08-29T04:00:00Z,2011-11-29T04:59:59Z,2011-08-29T14:24:36Z,2011-21972,0,0,0900006480f07901
FDA-2011-D-0597-0002,FDA,FDA-2011-D-0597,Draft Guidance for Industry; Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring,Other,Guidance,2011-08-29T04:00:00Z,2011,8,2011-08-29T04:00:00Z,,2019-10-21T13:49:09Z,,0,0,0900006480f07410